Skip to content
2000
Volume 26, Issue 3
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Background

The smooth muscle α-actin 2-antisense 1 (ACTA2-AS1), also known as ZXF1, is an emerging cancer-associated long non-coding RNA (lncRNA) that has garnered significant attention in recent years. ACTA2-AS1 is situated on human chromosome 10 at location 10q23.31, comprising five exons and a single transcript. The aberrant expression of ACTA2-AS1 has been noted in 10 malignant tumors, correlating significantly with unfavorable clinicopathological characteristics and poor patient prognosis.

Objective

This review encapsulates recent progress in ACTA2-AS1 research, examining its expression profile, biological functions, molecular mechanisms, and anticipated influence on cancer diagnosis, treatment, and prognosis, emphasizing its potential as a novel therapeutic target based on lncRNA and its prognostic utility as a biomarker.

Methods

Based on a comprehensive search of the PubMed database for the biological function of lncRNA ACTA2-AS1 in malignant tumors, the current research is systematically summarized and critically analyzed.

Results

ACTA2-AS1 plays a complex role in various biological processes in tumor cells, encompassing proliferation, apoptosis, and cell cycle arrest. It also contributes to migration, invasion, epithelial-mesenchymal transition (EMT), and drug resistance. Mechanistically, ACTA2-AS1 influences oncogenic or tumor-suppressive effects a complex regulatory network. It can adsorb specific 5 miRNAs as competitive endogenous RNAs (ceRNAs), thereby mitigating the suppression of downstream mRNA targets implicated in tumorigenesis (., SOX7, KLF9, CXCL2, BCL2L11, .) and modulating their downstream signaling pathways (., Wnt5a/PKC, SMAD3, mTOR, .), demonstrating a broad spectrum of dual roles in carcinogenesis and tumor suppression.

Conclusion

ACTA2-AS1 is a promising biomarker and molecular target for the treatment of cancer.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206381499250607114710
2025-06-19
2026-03-02

  • From This Site

    /content/journals/acamc/10.2174/0118715206381499250607114710
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. MattiuzziC. LippiG. Current cancer epidemiology.J. Epidemiol. Glob. Health20199421722210.2991/jegh.k.191008.001 31854162
     [Google Scholar]
  2. KaurR. BhardwajA. GuptaS. Cancer treatment therapies: Traditional to modern approaches to combat cancers.Mol. Biol. Rep.202350119663967610.1007/s11033‑023‑08809‑3 37828275
     [Google Scholar]
  3. LiuZ. ShiM. RenY. XuH. WengS. NingW. GeX. LiuL. GuoC. DuoM. LiL. LiJ. HanX. Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy.Mol. Cancer20232213510.1186/s12943‑023‑01738‑6 36797756
     [Google Scholar]
  4. BridgesM.C. DaulagalaA.C. KourtidisA. LNCcation: LncRNA localization and function.J. Cell Biol.20212202e20200904510.1083/jcb.202009045 33464299
     [Google Scholar]
  5. HermanA.B. TsitsipatisD. GorospeM. Integrated lncRNA function upon genomic and epigenomic regulation.Mol. Cell202282122252226610.1016/j.molcel.2022.05.027 35714586
     [Google Scholar]
  6. TanY.T. LinJ.F. LiT. LiJ.J. XuR.H. JuH.Q. LncRNA‐mediated posttranslational modifications and reprogramming of energy metabolism in cancer.Cancer Commun.202141210912010.1002/cac2.12108 33119215
     [Google Scholar]
  7. ZhangY. LncRNA-encoded peptides in cancer.J. Hematol. Oncol.20241716610.1186/s13045‑024‑01591‑0 39135098
     [Google Scholar]
  8. BhanA. SoleimaniM. MandalS.S. Long noncoding RNA and cancer: A new paradigm.Cancer Res.201777153965398110.1158/0008‑5472.CAN‑16‑2634 28701486
     [Google Scholar]
  9. SongY. GuoN.H. ZhengJ.F. LncRNA‐MALAT1 regulates proliferation and apoptosis of acute lymphoblastic leukemia cells via miR‐205‐PTK7 pathway.Pathol. Int.2020701072473210.1111/pin.12993 32754978
     [Google Scholar]
  10. ZhangR. PanT. XiangY. ZhangM. XieH. LiangZ. ChenB. XuC. WangJ. HuangX. ZhuQ. ZhaoZ. GaoQ. WenC. LiuW. MaW. FengJ. SunX. DuanT. Lai-Han. Leung, E.; Xie, T.; Wu, Q.; Sui, X. Curcumenol triggered ferroptosis in lung cancer cells via lncRNA H19/miR-19b-3p/FTH1 axis.Bioact. Mater.202213233610.1016/j.bioactmat.2021.11.013 35224289
     [Google Scholar]
  11. TangZ. KangB. LiC. ChenT. ZhangZ. GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis.Nucleic Acids Res.201947W1W556W56010.1093/nar/gkz430 31114875
     [Google Scholar]
  12. KurokiL. GuntupalliS.R. Treatment of epithelial ovarian cancer.BMJ2020371m377310.1136/bmj.m3773 33168565
     [Google Scholar]
  13. MorandS. DevanaboyinaM. StaatsH. StanberyL. NemunaitisJ. Ovarian cancer immunotherapy and personalized medicine.Int. J. Mol. Sci.20212212653210.3390/ijms22126532 34207103
     [Google Scholar]
  14. ZhangR. SiuM.K.Y. NganH.Y.S. ChanK.K.L. Molecular biomarkers for the early detection of ovarian cancer.Int. J. Mol. Sci.202223191204110.3390/ijms231912041 36233339
     [Google Scholar]
  15. LinC. ZhengM. YangY. ChenY. ZhangX. ZhuL. ZhangH. Knockdown of lncRNA ACTA2-AS1 reverses cisplatin resistance of ovarian cancer cells via inhibition of miR-378a-3p-regulated Wnt5a.Bioengineered20221349829983810.1080/21655979.2022.2061181 35412951
     [Google Scholar]
  16. LiY. YangZ. ChenJ. Mechanism underlying the regulation of lncRNA ACTA2-AS1 on CXCL2 by absorbing miRNA-532-5p as ceRNA in the development of ovarian cancer.Int. J. Clin. Exp. Pathol.2021145596607 34093945
     [Google Scholar]
  17. JoshiS.S. BadgwellB.D. Current treatment and recent progress in gastric cancer.CA Cancer J. Clin.202171326427910.3322/caac.21657 33592120
     [Google Scholar]
  18. MachlowskaJ. BajJ. SitarzM. MaciejewskiR. SitarzR. Gastric cancer: Epidemiology, risk factors, classification, genomic characteristics and treatment strategies.Int. J. Mol. Sci.20202111401210.3390/ijms21114012 32512697
     [Google Scholar]
  19. SmythE.C. NilssonM. GrabschH.I. van GriekenN.C.T. LordickF. Gastric cancer.Lancet20203961025163564810.1016/S0140‑6736(20)31288‑5 32861308
     [Google Scholar]
  20. RöckenC. Predictive biomarkers in gastric cancer.J. Cancer Res. Clin. Oncol.2023149146748110.1007/s00432‑022‑04408‑0 36260159
     [Google Scholar]
  21. AbdiE. Latifi-NavidS. Latifi-NavidH. SafaralizadehR. LncRNA polymorphisms and upper gastrointestinal cancer risk.Pathol. Res. Pract.202121815332410.1016/j.prp.2020.153324 33360092
     [Google Scholar]
  22. ZhangQ. WangC. YangY. XuR. LiZ. LncRNA and its role in gastric cancer immunotherapy.Front. Cell Dev. Biol.202311105294210.3389/fcell.2023.1052942 36875764
     [Google Scholar]
  23. HuZ. ChenZ. JiangW. FangD. PengP. YaoS. LuoM. WangL. SunZ. WangW. WangX. MaoH. AiF. ZhouP. Long noncoding RNA ACTA2-AS1 inhibits cell growth and facilitates apoptosis in gastric cancer by binding with miR-6720-5p to regulate ESRRB.Biochem. Genet.20236162672269010.1007/s10528‑023‑10399‑5 37222961
     [Google Scholar]
  24. BoucaiL. ZafereoM. CabanillasM.E. Thyroid cancer.JAMA2024331542543510.1001/jama.2023.26348 38319329
     [Google Scholar]
  25. BauerA.J. Pediatric thyroid cancer.Endocrinol. Metab. Clin. North Am.202049458961110.1016/j.ecl.2020.08.001 33153669
     [Google Scholar]
  26. PapaioannouM. ChortiA.G. ChatzikyriakidouA. GiannoulisK. BakkarS. PapavramidisT.S. MicroRNAs in papillary thyroid cancer: What is new in diagnosis and treatment.Front. Oncol.20221175509710.3389/fonc.2021.755097 35186709
     [Google Scholar]
  27. ShaoC. LiZ. ZhangC. ZhangW. HeR. XuJ. CaiY. Optical diagnostic imaging and therapy for thyroid cancer.Mater. Today Bio20221710044110.1016/j.mtbio.2022.100441 36388462
     [Google Scholar]
  28. WuS. ZhuJ. JiangT. CuiT. ZuoQ. ZhengG. LiG. ZhouJ. ChenX. Long non-coding RNA ACTA2-AS1 suppresses metastasis of papillary thyroid cancer via regulation of miR-4428/KLF9 axis.Clin. Epigenetics20241611010.1186/s13148‑023‑01622‑6 38195623
     [Google Scholar]
  29. HowardF.M. OlopadeO.I. Epidemiology of triple-negative breast cancer.Cancer J.202127181610.1097/PPO.0000000000000500 33475288
     [Google Scholar]
  30. Leon-FerreR.A. GoetzM.P. Advances in systemic therapies for triple negative breast cancer.BMJ2023381e07167410.1136/bmj‑2022‑071674 37253507
     [Google Scholar]
  31. YinL. DuanJ.J. BianX.W. YuS. Triple-negative breast cancer molecular subtyping and treatment progress.Breast Cancer Res.20202216110.1186/s13058‑020‑01296‑5 32517735
     [Google Scholar]
  32. LiY. ZhangH. MerkherY. ChenL. LiuN. LeonovS. ChenY. Recent advances in therapeutic strategies for triple-negative breast cancer.J. Hematol. Oncol.202215112110.1186/s13045‑022‑01341‑0 36038913
     [Google Scholar]
  33. PengY. HuangX. WangH. lncRNA ACTA2-AS1 predicts malignancy and poor prognosis of triple-negative breast cancer and regulates tumor progression via modulating miR-532-5p.BMC Mol. Cell Biol.20222313410.1186/s12860‑022‑00432‑7 35896973
     [Google Scholar]
  34. LiX. RamadoriP. PfisterD. SeehawerM. ZenderL. HeikenwalderM. The immunological and metabolic landscape in primary and metastatic liver cancer.Nat. Rev. Cancer202121954155710.1038/s41568‑021‑00383‑9 34326518
     [Google Scholar]
  35. MakiH. HasegawaK. Advances in the surgical treatment of liver cancer.Biosci. Trends202216317818810.5582/bst.2022.01245 35732434
     [Google Scholar]
  36. QiuC. FanH. TaoS. DengZ. LuoH. LiuF. ST8SIA6-AS1, a novel lncRNA star in liver cancer.Front. Cell Dev. Biol.202412143566410.3389/fcell.2024.1435664 39211393
     [Google Scholar]
  37. WangX. KangM. LiuC. LinT. HanX. JiangX. Current state and progress of research on the role of lncRNA in HBV-related liver cancer.Front. Cell. Infect. Microbiol.20211171489510.3389/fcimb.2021.714895 34869051
     [Google Scholar]
  38. ZhouR.J. LvH.Z. Knockdown of ACTA2 AS1 promotes liver cancer cell proliferation, migration and invasion.Mol. Med. Rep.20191932263227010.3892/mmr.2019.9856 30664183
     [Google Scholar]
  39. HendriksL.E.L. RemonJ. Faivre-FinnC. GarassinoM.C. HeymachJ.V. KerrK.M. TanD.S.W. VeronesiG. ReckM. Non-small-cell lung cancer.Nat. Rev. Dis. Primers20241017110.1038/s41572‑024‑00551‑9 39327441
     [Google Scholar]
  40. MiaoD. ZhaoJ. HanY. ZhouJ. LiX. ZhangT. LiW. XiaY. Management of locally advanced non‐small cell lung cancer: State of the art and future directions.Cancer Commun.2024441234610.1002/cac2.12505 37985191
     [Google Scholar]
  41. ZhuH. SunJ. ZhangC. LiP. TanC. YangM. ZhaoG. Cellular senescence in non-small cell lung cancer.Frontiers in Bioscience-Landmark2023281235710.31083/j.fbl2812357 38179738
     [Google Scholar]
  42. GinnL. ShiL. La MontagnaM. GarofaloM. LncRNAs in non-small-cell lung cancer.Noncoding RNA2020632510.3390/ncrna6030025 32629922
     [Google Scholar]
  43. HuQ. MaH. ChenH. ZhangZ. XueQ. LncRNA in tumorigenesis of non-small-cell lung cancer: From bench to bedside.Cell Death Discov.20228135910.1038/s41420‑022‑01157‑4 35963868
     [Google Scholar]
  44. LiuX. ZhangX. DuS. Long non-coding RNA ACTA2-AS1 inhibits the cisplatin resistance of non-small cell lung cancer cells through inhibiting autophagy by suppressing TSC2.Cell Cycle202221436837810.1080/15384101.2021.2020433 34985374
     [Google Scholar]
  45. SeguinL. DurandyM. FeralC.C. Lung adenocarcinoma tumor origin: A guide for personalized medicine.Cancers2022147175910.3390/cancers14071759 35406531
     [Google Scholar]
  46. SpellaM. StathopoulosG.T. Immune resistance in lung adenocarcinoma.Cancers202113338410.3390/cancers13030384 33494181
     [Google Scholar]
  47. WeiX. LiX. HuS. ChengJ. CaiR. Regulation of ferroptosis in lung adenocarcinoma.Int. J. Mol. Sci.202324191461410.3390/ijms241914614 37834062
     [Google Scholar]
  48. ChenZ. HuZ. SuiQ. HuangY. ZhaoM. LiM. LiangJ. LuT. ZhanC. LinZ. SunF. WangQ. TanL. LncRNA FAM83A-AS1 facilitates tumor proliferation and the migration via the HIF-1α/glycolysis axis in lung adenocarcinoma.Int. J. Biol. Sci.202218252253510.7150/ijbs.67556 35002507
     [Google Scholar]
  49. ZhaoM. XinX.F. ZhangJ.Y. DaiW. LvT.F. SongY. LncRNA GMDS‐AS1 inhibits lung adenocarcinoma development by regulating miR‐96‐5p/CYLD signaling.Cancer Med.2020931196120810.1002/cam4.2776 31860169
     [Google Scholar]
  50. YingK. WangL. LongG. LianC. ChenZ. LinW. ACTA2‐AS1 suppresses lung adenocarcinoma progression via sequestering miR‐378a‐3p and miR‐4428 to elevate SOX7 expression.Cell Biol. Int.202044122438244910.1002/cbin.11451 32808728
     [Google Scholar]
  51. BuskwofieA. David-WestG. ClareC.A. A review of cervical cancer: Incidence and disparities.J. Natl. Med. Assoc.2020112222923210.1016/j.jnma.2020.03.002 32278478
     [Google Scholar]
  52. FerrallL. LinK.Y. RodenR.B.S. HungC.F. WuT.C. Cervical cancer immunotherapy: Facts and hopes.Clin. Cancer Res.202127184953497310.1158/1078‑0432.CCR‑20‑2833 33888488
     [Google Scholar]
  53. SharmaS. DeepA. SharmaA.K. Current treatment for cervical cancer: An update.Anticancer. Agents Med. Chem.202020151768177910.2174/1871520620666200224093301 32091347
     [Google Scholar]
  54. LuoL. WangM. LiX. LuoC. TanS. YinS. LiuL. ZhuX. A novel mechanism by which ACTA2-AS1 promotes cervical cancer progression: Acting as a ceRNA of miR-143-3p to regulate SMAD3 expression.Cancer Cell Int.202020137210.1186/s12935‑020‑01471‑w 32774166
     [Google Scholar]
  55. BaidounF. ElshiwyK. ElkeraieY. MerjanehZ. KhoudariG. SarminiM.T. GadM. Al-HusseiniM. SaadA. Colorectal cancer epidemiology: Recent trends and impact on outcomes.Curr. Drug Targets2021229998100910.2174/18735592MTEx9NTk2y 33208072
     [Google Scholar]
  56. BillerL.H. SchragD. Diagnosis and treatment of metastatic colorectal cancer.JAMA2021325766968510.1001/jama.2021.0106 33591350
     [Google Scholar]
  57. IonescuV.A. GheorgheG. BacalbasaN. ChiotoroiuA.L. DiaconuC. Colorectal cancer: From risk factors to oncogenesis.Medicina2023599164610.3390/medicina59091646 37763765
     [Google Scholar]
  58. PanQ. HuangY. WangY. LiD. LeiC. LncRNA ACTA2-AS1 suppress colon adenocarcinoma progression by sponging miR-4428 upregulation BCL2L11.Cancer Cell Int.202121120310.1186/s12935‑021‑01769‑3 33845844
     [Google Scholar]
  59. WuX. PangQ. ZhiF. MaoX. HuY. Overexpression of long non-coding RNA ACTA2-AS1 inhibits the viability, proliferation, migration and invasion of colorectal cancer cells.Tissue Cell20227610176910.1016/j.tice.2022.101769 35325674
     [Google Scholar]
  60. BoganiG. Ray-CoquardI. ConcinN. NgoiN.Y.L. MoriceP. CarusoG. EnomotoT. TakeharaK. DenysH. LorussoD. ColemanR. VaughanM.M. TakanoM. ProvencherD.M. SagaeS. WimbergerP. PókaR. SegevY. KimS.I. KimJ.W. Candido dos ReisF.J. RamirezP.T. MarianiA. LeitaoM. MakkerV. Abu-RustumN.R. VergoteI. ZannoniG. TanD. McCormackM. PaoliniB. BiniM. RaspagliesiF. Benedetti PaniciP. Di DonatoV. MuziiL. ColomboN. PignataS. ScambiaG. MonkB.J. Endometrial carcinosarcoma.Int. J. Gynecol. Cancer202333214717410.1136/ijgc‑2022‑004073 36585027
     [Google Scholar]
  61. NeesL.K. HeubleinS. SteinmacherS. Juhasz-BössI. BruckerS. TempferC.B. WallwienerM. Endometrial hyperplasia as a risk factor of endometrial cancer.Arch. Gynecol. Obstet.2022306240742110.1007/s00404‑021‑06380‑5 35001185
     [Google Scholar]
  62. OtsukaI. Therapeutic benefit of systematic lymphadenectomy in node-negative uterine-confined endometrioid endometrial carcinoma: Omission of adjuvant therapy.Cancers20221418451610.3390/cancers14184516 36139675
     [Google Scholar]
  63. KongD. HouY. LiW. MaX. JiangJ. LncRNA‐ZXF1 stabilizes P21 expression in endometrioid endometrial carcinoma by inhibiting ubiquitination‐mediated degradation and regulating the miR‐378a‐3p/PCDHA3 axis.Mol. Oncol.202216381382910.1002/1878‑0261.12940 33751805
     [Google Scholar]
  64. YanH. BuP. Non-coding RNA in cancer.Essays Biochem.202165462563910.1042/EBC20200032 33860799
     [Google Scholar]
  65. StatelloL. GuoC.J. ChenL.L. HuarteM. Gene regulation by long non-coding RNAs and its biological functions.Nat. Rev. Mol. Cell Biol.20212229611810.1038/s41580‑020‑00315‑9 33353982
     [Google Scholar]
  66. LiJ. MingZ. YangL. WangT. LiuG. MaQ. Long noncoding RNA XIST: Mechanisms for X chromosome inactivation, roles in sex-biased diseases, and therapeutic opportunities.Genes Dis.2022961478149210.1016/j.gendis.2022.04.007 36157489
     [Google Scholar]
  67. Ghafouri-FardS. KhoshbakhtT. HussenB.M. TaheriM. AkbariD. N. A review on the role of PTENP1 in human disorders with an especial focus on tumor suppressor role of this lncRNA.Cancer Cell Int.202222120710.1186/s12935‑022‑02625‑8 35655204
     [Google Scholar]
  68. ZhouW. FengY. LinC. ChaoC.K. HeZ. ZhaoS. XueJ. ZhaoX.Y. CaoW. Yin Yang 1‐induced long noncoding RNA DUXAP9 drives the progression of oral squamous cell carcinoma by blocking cdk1‐mediated EZH2 degradation.Adv. Sci. (Weinh.)20231025220754910.1002/advs.202207549 37401236
     [Google Scholar]
  69. KuoF.C. NevilleM.J. SabaratnamR. Wesolowska-AndersenA. PhillipsD. WittemansL.B.L. Van DamA.D. LohN.Y. TodorčevićM. DentonN. KentistouK.A. JoshiP.K. ChristodoulidesC. LangenbergC. CollasP. KarpeF. PinnickK.E. HOTAIR interacts with PRC2 complex regulating the regional preadipocyte transcriptome and human fat distribution.Cell Rep.202240411113610.1016/j.celrep.2022.111136 35905723
     [Google Scholar]
  70. MouJ. BolieuE.L. PflugeisenB.M. AmorosoP.J. DevineB. BaldwinL.M. FrankL.L. JohnsonR.H. Delay in treatment after cancer diagnosis in adolescents and young adults: Does facility transfer matter?J. Adolesc. Young Adult Oncol.20198324325310.1089/jayao.2018.0128 30785806
     [Google Scholar]
  71. NguyenS.M. NguyenQ.T. NguyenL.M. PhamA.T. LuuH.N. TranH.T.T. TranT.V. ShuX.O. Delay in the diagnosis and treatment of breast cancer in Vietnam.Cancer Med.202110217683769110.1002/cam4.4244 34664428
     [Google Scholar]
  72. JavedN. El-FarM. VittorioT.J. Clinical markers in heart failure: A narrative review.J. Int. Med. Res.20245250300060524125433010.1177/03000605241254330 38779976
     [Google Scholar]
  73. XuZ. ChenY. MaL. YizhangC. LiuJ. GuoY. YuT. ZhangL. ZhuL. ShuY. Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment.Mol. Ther.202230103133315410.1016/j.ymthe.2022.01.046 35405312
     [Google Scholar]
  74. KokV.C. YuC.C. Cancer-derived exosomes: Their role in cancer biology and biomarker development.Int. J. Nanomedicine2020158019803610.2147/IJN.S272378 33116515
     [Google Scholar]
  75. ZhangS. WangX. WangD. Long non-coding RNA LINC01296 promotes progression of oral squamous cell carcinoma through activating the MAPK/ERK signaling pathway via the miR-485-5p/PAK4 axis.Arch. Med. Sci.201918378679910.5114/aoms.2019.86805 35591837
     [Google Scholar]
  76. YangK. LiL. ChenY. ManS. YangL. YangY. HeiN. ZhaoJ. The role of long non-coding RNA LINC01296 in oral squamous cell carcinoma: A study based on bioinformatics analysis and in vitro validation.J. Cancer202213377578310.7150/jca.60417 35154446
     [Google Scholar]
  77. ChenY. LiZ. ChenX. ZhangS. Long non-coding RNAs: From disease code to drug role.Acta Pharm. Sin. B202111234035410.1016/j.apsb.2020.10.001 33643816
     [Google Scholar]
  78. TanH. ZhangS. ZhangJ. ZhuL. ChenY. YangH. ChenY. AnY. LiuB. Long non-coding RNAs in gastric cancer: New emerging biological functions and therapeutic implications.Theranostics202010198880890210.7150/thno.47548 32754285
     [Google Scholar]
  79. TodenS. ZumwaltT.J. GoelA. Non-coding RNAs and potential therapeutic targeting in cancer.Biochim. Biophys. Acta Rev. Cancer20211875118849110.1016/j.bbcan.2020.188491 33316377
     [Google Scholar]
  80. KhorkovaO. StahlJ. JojiA. VolmarC.H. ZeierZ. WahlestedtC. Natural antisense transcripts as drug targets.Front. Mol. Biosci.2022997837510.3389/fmolb.2022.978375 36250017
     [Google Scholar]
  81. ArunG. AggarwalD. SpectorD.L. MALAT1 long non-coding RNA: Functional implications.Noncoding RNA2020622210.3390/ncrna6020022 32503170
     [Google Scholar]
  82. AgrawalN. DasaradhiP.V.N. MohmmedA. MalhotraP. BhatnagarR.K. MukherjeeS.K. RNA interference: Biology, mechanism, and applications.Microbiol. Mol. Biol. Rev.200367465768510.1128/MMBR.67.4.657‑685.2003 14665679
     [Google Scholar]
  83. S ZibittM. HartfordC.C.R. LalA. Interrogating lncRNA functions via CRISPR/Cas systems.RNA Biol.202118122097210610.1080/15476286.2021.1899500 33685382
     [Google Scholar]
  84. Bravo-VázquezL.A. Méndez-GarcíaA. Chamu-GarcíaV. RodríguezA.L. BandyopadhyayA. PaulS. The applications of CRISPR/Cas-mediated microRNA and lncRNA editing in plant biology: Shaping the future of plant non-coding RNA research.Planta202425923210.1007/s00425‑023‑04303‑z 38153530
     [Google Scholar]
  85. AmreddyN. BabuA. MuralidharanR. PanneerselvamJ. SrivastavaA. AhmedR. MehtaM. MunshiA. RameshR. Recent advances in nanoparticle-based cancer drug and gene delivery.Adv. Cancer Res.201813711517010.1016/bs.acr.2017.11.003 29405974
     [Google Scholar]
  86. GrimaldiA.M. IncoronatoM. SalvatoreM. SoricelliA. Nanoparticle-based strategies for cancer immunotherapy and immunodiagnostics.Nanomedicine201712192349236510.2217/nnm‑2017‑0208 28868980
     [Google Scholar]
  87. YooY.J. LeeC.H. ParkS.H. LimY.T. Nanoparticle-based delivery strategies of multifaceted immunomodulatory RNA for cancer immunotherapy.J. Control. Release202234356458310.1016/j.jconrel.2022.01.047 35124126
     [Google Scholar]
  88. MuskanM. AbeysingheP. CecchinR. BranscomeH. MorrisK.V. KashanchiF. Therapeutic potential of RNA-enriched extracellular vesicles: The next generation in RNA delivery via biogenic nanoparticles.Mol. Ther.20243292939294910.1016/j.ymthe.2024.02.025 38414242
     [Google Scholar]
  89. WinkleM. El-DalyS.M. FabbriM. CalinG.A. Noncoding RNA therapeutics — challenges and potential solutions.Nat. Rev. Drug Discov.202120862965110.1038/s41573‑021‑00219‑z 34145432
     [Google Scholar]
  90. LuoW. Nasopharyngeal carcinoma ecology theory: Cancer as multidimensional spatiotemporal “unity of ecology and evolution” pathological ecosystem.Theranostics20231351607163110.7150/thno.82690 37056571
     [Google Scholar]
/content/journals/acamc/10.2174/0118715206381499250607114710
Loading
Unveiling the Vital Role of ACTA2-AS1 in Human Cancers: Molecular Mechanisms and Clinical Applications
Anti-Cancer Agents in Medicinal Chemistry 26, 254 (2026); https://doi.org/10.2174/0118715206381499250607114710
/content/journals/acamc/10.2174/0118715206381499250607114710
/content/journals/acamc/10.2174/0118715206381499250607114710
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): ACTA2-AS1; cancer; clinical applications; LncRNA; therapeutic target; ZXF1

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test